AstraZeneca to Buy Icosavax for Up to $1.1 Billion
12 Dezembro 2023 - 4:47AM
Dow Jones News
By Ian Walker
AstraZeneca said it would buy U.S.-based clinical-stage
biopharmaceutical company Icosavax for up to $1.1 billion in a deal
that expands its vaccines and immune therapies late-stage
pipeline.
The pharmaceutical giant is offering $15 for each Icosavax share
held, a 43% premium to its closing market price of $10.49 on
Monday.
An extra $5.00 a share in cash could be paid depending upon
certain regulatory and sales milestones being met.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
December 12, 2023 02:32 ET (07:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Icosavax (NASDAQ:ICVX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Icosavax (NASDAQ:ICVX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
